End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
- 30 June 2009
- journal article
- review article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 54 (1), S97-S107
- https://doi.org/10.1016/j.jacc.2009.04.007
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- A meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEuropean Heart Journal, 2008
- Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertensionEuropean Journal of Heart Failure, 2007
- Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Cardiopulmonary Exercise Testing and Six-Minute Walk Correlations in Pulmonary Arterial HypertensionThe American Journal of Cardiology, 2006
- Efficacy and Safety of Sildenafil Added to Treprostinil in Pulmonary HypertensionThe American Journal of Cardiology, 2005
- Use of Placebo Controls in Clinical Trials DisputedScience, 1995
- Validity of the minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placeboThe American Journal of Cardiology, 1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Natural history of pulmonary hemodynamics in primary pulmonary hypertensionAmerican Heart Journal, 1987
- Primary pulmonary hypertension: natural history and the importance of thrombosis.Circulation, 1984